Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting

Medical Science Monitor

Volumn 11, Issue 10, 2005, Pages

  Janicki, Piotr K ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

5 HT3 receptor antagonists; CYP2D6; Drug metabolism; Granisetron; Polymorphisms; PONV

Indexed keywords

AMIODARONE; ANTIEMETIC AGENT; CIMETIDINE; CLOZAPINE; CODEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DOLASETRON MESILATE; DRUG METABOLITE; FLUPHENAZINE; FLUVOXAMINE; GRANISETRON; IMIPRAMINE; ONDANSETRON; PALONOSETRON; PARACETAMOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SEROTONIN 3 ANTAGONIST; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; UNINDEXED DRUG; UNSPECIFIC MONOOXYGENASE; WARFARIN;

ALLELE; ANASTOMOSIS DEHISCENCE; ASPIRATION PNEUMONIA; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DUPLICATE GENE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; ESOPHAGUS RUPTURE; FATIGUE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEALTH CARE COST; HUMAN; LIVER METABOLISM; MALAISE; META ANALYSIS; POSTOPERATIVE NAUSEA AND VOMITING; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; POSTOPERATIVE NAUSEA AND VOMITING; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS;

EID: 26944481543     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Gan TJ. Postoperative nausea and vomiting - can it be eliminated? JAMA, 2002; 287: 1233-36
2. Apfel CC, Korttila K, Abdalla M et al: A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med, 2004, 350: 2441-51
3. Touw DJ: Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact, 1997; 14: 55-82
4. Caraco Y: Genes and the response to drugs. N Engl J Med, 2004; 351: 2867-69
5. Roepstorff V, Ostenfeldt N, Autrup H: Extracts of airborne particulates collected at different locations in the Copenhagen area induce the expression of cytochrome P-450IA1. J Toxicol Environ Health, 1990; 30: 225-37
6. McElroy S, Sachse C, Brockmoller J et al: CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci, 2000; 2: E33
7. Obase Y, Shimoda T, Kawano T et al: Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther, 2003; 73: 468-74
8. Eap CB, Bender S, Sirot EJ et al: Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol, 2004; 24: 214-19
9. Gasche Y, Daali Y, Fathi M et al: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med, 2004; 351: 2827-31
10. Chan WK, Nguyen LT, Miller VT, Harris RZ: Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci, 1998; 62: L135-L142
11. Moody DE, Walsh SL, Rollins DE et al: Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin Pharmacol Ther, 2004; 76: 154-66
12. Honig PK, Wortham DC, Zamani K et al: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 1993; 269: 1513-18
13. Niemi M, Backman JT, Fromm MF et al: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet, 2003; 42: 819-50
14. Wolf CR, Smith G: Pharmacogenetics. Br Med Bull, 1999; 55: 366-86
15. Phillips KA, Veenstra DL, Oren E et al: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 2001; 286: 2270-79
16. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: over-view and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol, 2004; 369: 23-37
17. Institute of Environmental Medicine (Karolinska Institute): CYP2D6 allele nomenclature. Home Page of the Human Cytochrome P450 (QT) Allele Nomenclature Committee. 4-18-2005, 4-27-2005.
18. Mahgoub A, Idle JR, Dring LG et al: Polymorphic hydroxylation of Debrisoquine in man. Lancet, 1977; 2: 584-86
19. Stamer UM, Bayerer B, Wolf S et al: Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem, 2002; 48: 1412-17
20. Mitsunaga Y, Kubota T, Ishiguro A et al: Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutat Res, 2002; 505: 83-85
21. Chen S, Chou WH, Blouin RA et al: The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther, 1996; 60: 522-34
22. Chou WH, Yan FX, de Leon J et al: Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol, 2000; 20: 246-51
23. Ran T, Wohlleben G, Wuttke H et al: CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther, 2004; 75: 386-93
24. Grasmader K, Verwohlt PL, Rietschel M et al: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol, 2004; 60: 329-36
25. Brockmoller J, Kirchheiner J, Schmider J et al: The impact of the CVP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther, 2002; 72: 438-52
26. Sallee FR, DeVane CL, Ferrell RE: Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol, 2000; 10: 27-34
27. Williams DG, Patel A, Howard RF: Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth, 2002; 89: 839-45
28. Johansson I, Lundqvist E, Berilsson L et al: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA, 1993; 90: 11825-29
29. McLellan RA, Oscarson M, Seidegard J et al: Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics, 1997; 7: 187-91
30. Aklillu E, Persson I, Bertilsson L et al: Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther, 1996; 278: 441-46
31. Luo HR, Aloumanis V, Lin KM et al: Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics, 2004; 4: 395-401
32. Scordo MG, Caputi AP, D'Arrigo C et al: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res, 2004; 50: 195-200
33. Agundez JA, Ledesma MC, Ladero JM, Benitez J: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther, 1995; 57: 265-69
34. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet, 1997; 60: 284-95
35. Kawanishi C, Lundgren S, Agren H, Bertilsson L: Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of non response. A pilot study. Eur J Clin Pharmacol, 2004; 59: 803-7
36. Bertilsson L, Dahl ML, Sjoqvist F et al: Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 1993; 341: 63
37. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C: The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol, 1986; 22: 49-53
38. Shin JG, Soukhova N, Flockhart DA: Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos, 1999; 27: 1078-84
39. Apfel CC, Laara E, Koivuranta M et al: A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology, 1999; 91: 693-700
40. Gan TJ, Meyer T, Apfel CC et al: Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg, 2003; 97: 62-71
41. Glaxo Smith Kline: Zofran (ondansetron hydrochloride) injection prescribing information. Glaxo Smith Kline, 2005, 4-27-2005
42. Glaxo Smith Kline: Zofran (ondansetron hydrochloride) tablets prescribing information. Glaxo Smith Kline, 2005, 4-27-2005
43. MGI Pharma: Aloxi (palonosetron HCl injection) prescribing information. MGI Pharma, 2004, 4-27-2005
44. Avenus Pharmaceuticals: Anzemet injection (dolasetron mesylate injeciton) prescribing information. Aventis Pharmaceuticals, 2003, 4-27-2005
45. Aventis Pharmaceuticals: Anzemet tablets (dolasetron mesylate) prescribing information. Aventis Pharmaceuticals, 2003, 4-27-2005
46. Roche Pharmaceuticals: Kytril (granisetron hydrochloride) injection complete product information. Roche Pharmaceuticals, 2004, 4-27-2005
47. Roche Pharmaceuticals: Kytril (granisetron hydrochloride) tablets and oral solution complete product information. Roche Pharmaceuticals, 2001, 4-27-2005
48. Novartis Pharmaceuticals: Navoban (tropisetron) prescribing information. Novartis Pharmaceuticals Australia Pty Ltd. 10-22-1997, 4-27-2005
49. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs, 2005; 19: 225-38
50. van Wijngaarden I, Tulp MT, Soudijn W: The concept of selectivity in 5-HT receptor research. Eur J Pharmacol, 1990; 188: 301-12
51. Aapro M: Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist, 2004; 9: 673-86
52. Firkusny L, Kroemer HK, Eichelbaum M: In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol, 1995; 49: 1777-84
53. Fischer V, Vickers AE, Heitz F et al: The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos, 1994; 22: 269-74
54. Sanwald P, David M, Dow J: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos, 1996; 24: 602-9
55. Hesselink DA, van Schaik RH, van der Heiden IP et al: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54
56. Kim MK, Cho JY, Lim HS et al: Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol, 2003; 59: 111-16
57. Kamanabrou D. Intravenous granisetron - establishing the optimal dose. The Granisetron Study Group. Eur J Cancer, 1992; 28A(Suppl.l): S6-11
58. Philip BK, McLeskey CH, Chelly JE et al: Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. J Clin Anesth, 2000; 12: 1-8
59. Kaiser R, Sezer O, Papies A et al: Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochronic P-450 2D6 genotypes. J Clin Oncol, 2002; 20: 2805-11
60. Candiotti KA, Birnbach DJ, Lubarsky DA et al: The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology, 2005; 102: 543-49
61. Janicki PK, Schuler G, Jarzembowski TM, Rossi M: Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. In submission, 2005
62. Bernal ML, Sinnes B, Johansson I et al: Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics, 1999; 9: 657-6063.
63. Norton RM: Pharmacogenomics and individualized ding therapy. 2D6 testing for specific drug classes. Medscape, 2005, 4-27-2005